Treatment of renal osteodystrophy

被引：1
作者：
Gal-Moscovici A. [1 ,2 ]
Sprague S.M. [2 ,4 ]
Lerma E.V. [3 ]
机构：
[1] Hadassah Hospital Medical Center, Hebrew University, Ein Keren, Jeruslaem
[2] Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
[3] Section of Nephrology, University of Illinois at Chicago, College of Medicine/Associates in Nephrology, Chicago, IL
[4] Evanston, IL 60201
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2007年 / 5卷 / 1期
关键词：
Cinacalcet; Parathyroidectomy; Phosphate binders; Renal osteodystrophy; Vitamin D receptor agonist;
D O I：
10.1007/BF02736669
中图分类号：
学科分类号：
摘要：
Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist's concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy. © Copyright 2007 by Humana Press Inc. All rights of any nature whatsoever reserved.
引用
收藏
页码：27 / 38
页数：11
相关论文
共 115 条
[81]  
Christiansen C., Christensen M.S., Melsen F., Rodbro P., DeLuca H.F., Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D, Clin Nephrol, 15, pp. 18-22, (1981)
[82]  
Fratzl-Zelman N., Glantschnig H., Rumpler M., Et al., The expression of matrix metalloproteinase-13 and osteocalcin in mouse osteoblasts is related to osteoblastic differentiation and is modulated by 1,25-dihydroxyvitamin D3 and thyroid hormones, Cell Biol Int, 27, pp. 459-468, (2003)
[83]  
Staal A., Geertsma-Kleinekoort W.M., Van Den Bemd G.J., Et al., Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: Interaction with the bone-derived growth factors TGF-beta and IGF-I, J Bone Miner Res, 13, pp. 36-43, (1998)
[84]  
Gram J., Junker P., Nielsen H.K., Bollerslev J., Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males, Bone, 18, pp. 539-544, (1996)
[85]  
Bro S., Olgaard K., Effects of excess PTH on nonclassical target organs, Am J Kidney Dis, 30, pp. 606-620, (1997)
[86]  
Silver J., Russell J., Sherwood L.M., Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells, Proc Natl Acad Sci U S A, 82, pp. 4270-4273, (1985)
[87]  
Salusky I.B., Goodman W.G., Adynamic renal osteodystrophy: Is there a problem?, J Am Soc Nephrol, 12, pp. 1978-1985, (2001)
[88]  
Salusky I.B., Kuizon B.D., Belin T.R., Et al., Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration, Kidney Int, 54, pp. 907-914, (1998)
[89]  
Goodman W.G., Ramirez J.A., Belin T.R., Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy, Kidney Int, 46, pp. 1160-1166, (1994)
[90]  
Goodman W.G., Salusky I.B., Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy, Contrib Nephrol, 90, pp. 189-195, (1991)
3456789101112